Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are up 18% this past week, but still in the red over the last three yearsSimply Wall St • 26 days ago
It is a pleasure to report that the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) is up 99% in the last quarter. But...
Share to Feed
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...
Adaptimmune Therapeutics plc (NASDAQ:ADAP Get Free Report) fell 2.1% on Tuesday . The company traded as low as $1.41 and last traded at $1.41. 62,343 shares were traded during trading, a...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP Research Report), Elevation Oncology...
Key Financial Highlights and Business UpdatesRelated Stocks: ADAP...
Adaptimmune Therapeutics (ADAP Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy...
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed...
Adaptimmune Therapeutics plc (NASDAQ:ADAP Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest...
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc...
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $1.38, but opened at $1.45. Adaptimmune...